WINTON GROUP Ltd Buys 136,820 Shares of Pediatrix Medical Group, Inc. $MD

WINTON GROUP Ltd increased its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 174.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 215,096 shares of the company’s stock after purchasing an additional 136,820 shares during the period. WINTON GROUP Ltd owned approximately 0.25% of Pediatrix Medical Group worth $3,603,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Canada Pension Plan Investment Board acquired a new position in Pediatrix Medical Group in the second quarter valued at about $83,000. Quantbot Technologies LP acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $99,000. Smartleaf Asset Management LLC increased its stake in shares of Pediatrix Medical Group by 10.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after acquiring an additional 601 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Pediatrix Medical Group by 219.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,685 shares of the company’s stock valued at $110,000 after acquiring an additional 5,278 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $145,000. Institutional investors own 97.71% of the company’s stock.

Insider Activity at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. The trade was a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. UBS Group reduced their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a report on Friday, February 20th. Finally, Truist Financial lowered their price objective on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and a consensus target price of $19.80.

Pediatrix Medical Group Price Performance

NYSE MD opened at $20.10 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of 10.36 and a beta of 0.79. The business has a 50 day simple moving average of $21.08 and a 200 day simple moving average of $19.98. Pediatrix Medical Group, Inc. has a 52-week low of $11.84 and a 52-week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). The company had revenue of $493.77 million during the quarter, compared to the consensus estimate of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.51 EPS. Analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.